<DOC>
	<DOCNO>NCT00658359</DOCNO>
	<brief_summary>This study follow transplant patient Study A3921030 monitor long term safety , tolerability efficacy 5 additional year , except Portugal study follow transplant patient Month 36 posttransplant . Patients continue study medication previously assign .</brief_summary>
	<brief_title>Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Subjects successfully complete Study A3921030 Subjects wait list second kidney transplant nonrenal organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>JAK3 inhibitor</keyword>
	<keyword>kidney transplantation</keyword>
</DOC>